Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
classes:
Antidepressant (1) ·
Anxiolytic (1) ·
Dual orexin receptor antagonist (DORA) (1) ·
non-stimulant ADHD agent (1) ·
Selective norepinephrine reuptake inhibitor (NRI) with 5HT1A partial agonism (1) ·
SNRI (1) ·
the first approved (1) ·
[[:Category:Skeletal muscle relaxants|Skeletal muscle relaxant (centrally-acting)]] (1)
mechanism:
None (1) ·
Competitive antagonist at OX1R and OX2R. First-in-class DORA. Receptor dissociation slower than lemborexant or daridorexant. (1) ·
Selective NET inhibitor (no significant DAT activity, distinguishes from amphetamine/methylphenidate). Also: 5HT1A receptor partial agonism, 5HT2B and 5HT7 receptor antagonism. The serotonergic actions may underlie better tolerability and possibly different efficacy spectrum than atomoxetine. (1) ·
Serotonin–norepinephrine reuptake inhibition (balanced) (1)
uses:
ADHD in children (6+), adolescents, and adults (FDA-approved 2021 for pediatric, 2022 for adult) (1) ·
Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) ·
Insomnia (sleep onset and/or maintenance) in adults (FDA-approved August 2014). Also studied for insomnia in mild-moderate Alzheimer disease. (1) ·
'"`UNIQ--vote-00000015-QINU`"', '"`UNIQ--vote-00000016-QINU`"' (1)
starting dose:
None (1) ·
10 mg PO 30 min before bedtime (with ≥7 hours of sleep planned) (1) ·
Oral: 1500 mg PO QID for 2-3 days (load), then 750-1500 mg QID maintenance. IV/IM: 1000 mg every 8 hours for acute spasm (1) ·
Pediatric 6-11: 100 mg PO daily, titrate weekly to max 400 mg. Adolescent 12-17: 200 mg, max 400 mg. Adult: 200 mg, max 600 mg. (1)
preparations:
fda max:
routes:
onset:
duration:
halflife: (Click arrow to add another value)
bioavailability:
pregnancy:
Error in "where" parameter: the string "--" cannot be used within #cargo_query.
There are no results for this report.